The company, which trades under the ticker BLLN, centers its operations around a proprietary single-molecule next-generation sequencing platform. This technology utilizes Quantitative Counting Templates to identify and quantify genetic targets at the physical limit of detection, down to individual DNA molecules.

Investors and industry observers can follow the discussion via a live webcast hosted on the BillionToOne investor relations website. An archived version of the session will remain available on the platform following the conclusion of the event.